CONTROL

12/101 (muscle)
NVP-TAE684) and with GSK3 inhibitors (0.5μM BIO, 1.0μM CHIR99021) for 24h and analysed by western blot for pY-GSK3, total GSK3 and ALK. Analysis confirmed absence of ALK in this cell line and a lower amount of pY-GSK3 than Kelly cell line (see Figure 7D ). Treatment with ALK inhibitors showed that CTB did not affect the pY-GSK3 content compared to untreated cells, however AZD and NVP seem to have reduced total GSK3 and pY-GSK3 significantly, possibly due to loss of cell viability. GSK3 inhibitors maintained total-GSK3 unaffected, however pY-GSK3 expression was not detected. (C, D) Relative levels of pY-GSK3α (C) and pY-GSK3β (D) to loading control. 
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